← All trials
NCT04716452
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2021
- Primary completion
- Dec 30, 2021
- Completion date
- Jun 30, 2022
- First posted
- Jan 20, 2021
- Last posted
- Jan 20, 2021
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Keystone Nano, IncLead sponsor
- Memorial Sloan-Kettering Cancer CenterCollaborator
- University of VirginiaCollaborator
- Pennsylvania State UniversityCollaborator
- Keystone Nano, IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.